-
公开(公告)号:US20100113440A1
公开(公告)日:2010-05-06
申请号:US12526553
申请日:2008-02-08
申请人: Anna Karin Gertrud Linnea Belfrage , Björn Olof Classon , Karin Charlotta Lindquist , Karl Magnus Nilsson , Pierre Jean-Marie Bernard Raboisson , Åsa Annica Kristina Rosenquist , Bertil Bengt Samuelsson , Horst Jürgen Wähling
发明人: Anna Karin Gertrud Linnea Belfrage , Björn Olof Classon , Karin Charlotta Lindquist , Karl Magnus Nilsson , Pierre Jean-Marie Bernard Raboisson , Åsa Annica Kristina Rosenquist , Bertil Bengt Samuelsson , Horst Jürgen Wähling
IPC分类号: A61K31/5377 , A61K31/506 , A61K31/395 , C07D245/04 , C07D413/14 , C07D403/12
CPC分类号: C07K5/06165 , A61K38/00 , C07D403/12 , Y02A50/385 , Y02A50/387
摘要: Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
摘要翻译: 包括其立体异构体或N-氧化物的式(I)化合物,其药学上可接受的加成盐或其药学上可接受的加成溶剂合物; 用作HCV抑制剂; 制备这些化合物的方法以及包含这些化合物作为活性成分的药物组合物。
-
公开(公告)号:US08937080B2
公开(公告)日:2015-01-20
申请号:US12526553
申请日:2008-02-08
申请人: Pierre Jean-Marie Bernard Raboisson , Anna Karin Gertrud Linnea Belfrage , Björn Olof Classon , Karin Charlotta Lindquist , Karl Magnus Nilsson , Åsa Annica Kristina Rosenquist , Bertil Bengt Samuelsson , Horst Jürgen Wähling
发明人: Pierre Jean-Marie Bernard Raboisson , Anna Karin Gertrud Linnea Belfrage , Björn Olof Classon , Karin Charlotta Lindquist , Karl Magnus Nilsson , Åsa Annica Kristina Rosenquist , Bertil Bengt Samuelsson , Horst Jürgen Wähling
IPC分类号: A61K31/506 , C07D245/02 , C07K5/078 , C07D403/12 , A61K38/00
CPC分类号: C07K5/06165 , A61K38/00 , C07D403/12 , Y02A50/385 , Y02A50/387
摘要: Compounds of the formula I: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
摘要翻译: 式I化合物:包括其立体异构体或N-氧化物,药学上可接受的加成盐或其药学上可接受的加成溶剂合物; 用作HCV抑制剂; 制备这些化合物的方法以及包含这些化合物作为活性成分的药物组合物。
-
公开(公告)号:US07659245B2
公开(公告)日:2010-02-09
申请号:US11995900
申请日:2006-07-28
申请人: Kenneth Alan Simmen , Herman Augustinus De Kock , Pierre Jean-Marie Bernard Raboisson , Lili Hu , Karin Charlotta Lindquist , Mats Stefan Lindström , Anna Karin Gertrud Linnea Belfrage , Horst Jürgen Wähling , Karl Magnus Nilsson , Bengt Bertil Samuelsson , Åsa Annica Kristina Rosenquist , Sven Crister Sahlberg , Hans Kristian Wallberg , Pia Cecilia Kahnberg , Björn Olof Classon
发明人: Kenneth Alan Simmen , Herman Augustinus De Kock , Pierre Jean-Marie Bernard Raboisson , Lili Hu , Karin Charlotta Lindquist , Mats Stefan Lindström , Anna Karin Gertrud Linnea Belfrage , Horst Jürgen Wähling , Karl Magnus Nilsson , Bengt Bertil Samuelsson , Åsa Annica Kristina Rosenquist , Sven Crister Sahlberg , Hans Kristian Wallberg , Pia Cecilia Kahnberg , Björn Olof Classon
IPC分类号: A61K38/00
CPC分类号: C07D487/10 , C07D245/04
摘要: Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(═O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; denotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl; R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl; R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.
摘要翻译: 式I的化合物及其N-氧化物,盐和立体异构体,其中A是OR 1,NHS(-O)p R 2; 其中; R 1是氢,C 1 -C 6烷基,C 0 -C 3亚烷基环羰基,C 0 -C 3亚烷基 - 杂环基; R 2是C 1 -C 6烷基,C 0 -C 3亚烷基环羰基,C 0 -C 3亚烷基杂环基; p独立地为1或2; n为3,4,5或6; “img id =”CUSTOM-CHARACTER-00001“he =”2.46mm“wi =”5.25mm“file =”US07659245-20100209-P00001.TIF“alt =”custom character“img-content =”character“img-format =“tif”/>表示可选的双键; L为N或CRz; Rz是H或与星号碳形成双键; Rq为H或当L为CRz时,Rq也可为C1-C6烷基; Rr是喹唑啉基,任选地被一个两个或三个独立地选自C 1 -C 6烷基,C 1 -C 6烷氧基,羟基,卤素,卤代C 1 -C 6烷基,氨基,单或二烷基氨基,单或二烷基氨基羰基,C 1 -C 6烷基 - 羰基氨基 ,C 0 -C 3亚烷基环基和C 0 -C 3亚烷基杂环基; R 5是氢,C 1 -C 6烷基,C 1 -C 6烷氧基C 1 -C 6烷基或C 3 -C 7环烷基; R 6是氢,C 1 -C 6烷基,C 1 -C 6烷氧基,C 0 -C 3亚烷基环基,C 0 -C 3亚烷基 - 杂环基,羟基,溴,氯或氟可用于治疗或预防黄病毒感染如HCV。
-
-